Literature DB >> 8784806

Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle.

P Juzans1, J X Comella, J Molgo, L Faille, D Angaut-Petit.   

Abstract

The marked outgrowth of the motor nerve terminal arborization triggered by an in vivo local injection of Clostridium botulinum type-A toxin in the mouse levator auris longus muscle was studied with morphological and immunochemical approaches. The increase in total nerve terminal length depended on the time elapsed after toxin administration and was due to both increased number of terminal branches and branch length as revealed by a quantitative morphological analysis of whole mounts using the combined cholinesterase-silver stain. Nerve terminal sprouts increased in number, length and complexity even after the functional recovery of neuromuscular transmission had occurred as revealed by electrophysiological examination. Although we cannot exclude that transmitter release sites from the original nerve terminal arborization may still be functional after botulinum type-A toxin (BoTx-A) treatment, it is likely that newly formed functional release sites on the sprouts play a major role in the functional recovery of neuromuscular transmission. The presence of an immunoreactivity to synaptophysin and synaptotagmin-II, integral proteins of synaptic vesicles, gives support to our previous findings suggesting that nerve terminal sprouts have the molecular machinery for acetylcholine release.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784806     DOI: 10.1016/0960-8966(96)00041-7

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  30 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Longitudinal neurophysiological assessment of intramuscular type-A botulin toxin in healthy humans.

Authors:  L Lispi; L Leonardi; A Petrucci
Journal:  Neurol Sci       Date:  2017-11-11       Impact factor: 3.307

Review 4.  Botulinum toxin type A therapy for cervical dystonia.

Authors:  Mafalda Castelão; Raquel E Marques; Gonçalo S Duarte; Filipe B Rodrigues; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2017-12-12

5.  Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

Authors:  A de Paiva; F A Meunier; J Molgó; K R Aoki; J O Dolly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

6.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

7.  Distinct muscarinic acetylcholine receptor subtypes contribute to stability and growth, but not compensatory plasticity, of neuromuscular synapses.

Authors:  Megan C Wright; Srilatha Potluri; Xueyong Wang; Eva Dentcheva; Dinesh Gautam; Alan Tessler; Jürgen Wess; Mark M Rich; Young-Jin Son
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

8.  Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons.

Authors:  Julie A Coffield; Xiuzhen Yan
Journal:  J Pharmacol Exp Ther       Date:  2009-04-16       Impact factor: 4.030

Review 9.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06

10.  Ciliary neurotrophic factor is not required for terminal sprouting and compensatory reinnervation of neuromuscular synapses: re-evaluation of CNTF null mice.

Authors:  Megan C Wright; Young-Jin Son
Journal:  Exp Neurol       Date:  2007-03-21       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.